News

Study demonstrates differences in mutation frequencies between African American and Caucasian myeloma patients

A study, recently published in PLoS Genetics, has demonstrated significant differences in mutation frequencies between African American (AA) and Caucasian (CA) patients with newly diagnosed myeloma. Researchers at the University of Southern California analysed data from the Multiple Myeloma Research Foundation’s CoMMpass study to determine genetic alterations in myeloma in the context of self-reported race.…

Details

Janssen submits application to EMA for the use of daratumumab in newly diagnosed myeloma patients

Janssen has submitted an application to the European Medicines Agency (EMA) to extend the marketing authorisation for daratumumab (Darzalex®) to include its use in combination with bortezomib (Velcade®), melphalan and prednisone as a treatment for newly diagnosed myeloma patients who are ineligible for an autologous stem cell transplant (ASCT). This decision is based on the…

Details

2017 ASH abstracts now available to view

This year’s American Society for Hematology (ASH) Annual Meeting final programme and abstracts are now available to view. Over 400 clinical and non-clinical abstracts specifically related to myeloma are being presented at the meeting being held on 9 – 12 December 2017 in Atlanta, USA. Highlights include: The latest results from the Myeloma XI trial…

Details

Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details

Phase III carfilzomib trial meets primary endpoint

Amgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…

Details

MUK nine opens for recruitment

Myeloma UK is pleased to announce that MUK nine is the latest trial in the Myeloma UK Clinical Trial Network (CTN) open to patient recruitment. The aim of MUK nine is to stratify treatment for high-risk myeloma patients. Up to 700 newly diagnosed myeloma patients will be recruited and screened at the Institute of Cancer…

Details

SMC approves restricted use of daratumumab monotherapy for relapsed and refractory myeloma

The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex®) monotherapy as a fourth line treatment option for relapsed and refractory myeloma patients in Scotland, who have previously received treatment with a proteasome inhibitor and immunomodulatory drug. This decision is based on the pooled analysis of results from two clinical trials, MMY2002 and…

Details